Evidence map›Paper›PMID 29317211›Full record

ArticleAmerican journal of ophthalmology2018

Baseline 24-2 Central Visual Field Damage Is Predictive of Global Progressive Field Loss.

Aakriti Garg, C Gustavo De Moraes, George A Cioffi, Christopher A Girkin, Felipe A Medeiros, Robert N Weinreb, Linda M Zangwill, Jeffrey M Liebmann

Abstract readMulticenter Study
In one paragraph

Article in American journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Predicting 60-4 visual field tests using 3D facial reconstruction.The British journal of ophthalmology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Observational
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aakriti GargBernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, New York.
C Gustavo De MoraesBernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, New York. Electronic address: gustavo.demoraes@columbia.edu.
George A CioffiBernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, New York.
Christopher A GirkinSchool of Medicine, University of Alabama-Birmingham, Birmingham, Alabama.
Felipe A MedeirosHamilton Glaucoma Center, Department of Ophthalmology, University of California-San Diego, San Diego, California.
Robert N WeinrebHamilton Glaucoma Center, Department of Ophthalmology, University of California-San Diego, San Diego, California.
Linda M ZangwillHamilton Glaucoma Center, Department of Ophthalmology, University of California-San Diego, San Diego, California.
Jeffrey M LiebmannBernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, New York.

Funding

African Descent And Glaucoma Evaluation Study (ADAGES)U10EY014267 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2002 to 2010
$13.2M
Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
VISUAL FUNCTION IN GLAUCOMA AND OCULAR HYPERTENSIONR01EY008208 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MEDEIROS, FELIPE · 1990 to 2010
$5.7M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progressionR01EY026574 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAZIO, MASSIMO ANTONIO, GIRKIN, CHRISTOPHER ANTHONY · 2017 to 2020
$2.6M
Structural and Functional Progression of Glaucomatous Damage to the MaculaR01EY025253 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DE MORAES, CARLOS GUSTAVO · 2015 to 2017
$1.2M
Quantification of Glaucomatous Optic NeuropathyK23EY013959 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GIRKIN, CHRISTOPHER ANTHONY · 2002 to 2006
$994k
NEI NIH HHS K23 EY013959NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY008208NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY025253NEI NIH HHS R01 EY026574NEI NIH HHS R01 EY027510NEI NIH HHS U10 EY014267
6 · The paper itself

Abstract

purposeCentral visual field (VF) damage in glaucoma patients can significantly hinder daily activities. The present study investigates whether the presence of localized baseline damage to the central 10 degrees of the VF is predictive of faster global mean deviation (MD) progression.

designProspective cohort study.

methodsEyes from the multicenter African Descent and Glaucoma Evaluation Study (ADAGES) with established glaucoma and VF loss and a minimum of 5 24-2 VFs were eligible. Baseline central 24-2 damage was defined as any of the 12 central-most points with total deviation (TD) values at P < 0.5% on 2 consecutive examinations. Progression was determined using trend-based and event-based criteria: (1) rates of MD change significantly faster than zero and (2) >-5 dB MD loss over the entire follow-up.

resultsA total of 827 eyes of 584 patients were studied. Mean rate of MD change of the entire sample was -0.15 dB/year (95% CI: -0.19 to -0.12, P < .001). Eyes with baseline central damage progressed faster than those without (difference: β

conclusionThe presence of central VF damage at baseline is significantly associated with more rapid global progression. Detection of central VF damage aids in stratification of high-risk patients who may need intensive surveillance and aggressive treatment.

Indexed as

Visual Field TestsAdultAgedBlack or African AmericanDisease ProgressionFalse Positive ReactionsFemaleFollow-Up StudiesGlaucomaHumansIntraocular PressureMaleMiddle AgedOptic DiskOptic Nerve DiseasesPredictive Value of Tests

Identifiers

PMID29317211
PMCPMC5837938

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.